Literature DB >> 17015632

In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Lucio Vera-Cabrera1, Barbara A Brown-Elliott, Richard J Wallace, Jorge Ocampo-Candiani, Oliverio Welsh, Sung Hak Choi, Carmen A Molina-Torres.   

Abstract

DA-7867 and DA-7157 are oxazolidinones active against pathogenic aerobic actinomycetes including Nocardia spp. and Mycobacterium tuberculosis. However, the activity of these drugs against nontuberculous mycobacterium (NTM) species is not known. In this work, we compared the susceptibilities of 122 clinical isolates and 29 reference species of both rapidly growing and slowly growing mycobacteria to linezolid, DA-7867, and DA-7157 by the broth microdilution method. The MICs for 50 and 90% of the strains tested (MIC50s and MIC90s, respectively) of DA-7867 and DA-7157 were lower than those of linezolid. In all of the cases, a MIC90 of <8 microg/ml was observed for all of the species tested in both groups of NTM. For M. kansasii and M. marinum isolates, the MIC90s of both DA-7867 and DA-7157 were less than 0.5 microg/ml. These results demonstrate the potential of these compounds to treat NTM infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015632      PMCID: PMC1693997          DOI: 10.1128/AAC.00763-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Victor M Velazquez-Moreno; Sung Hak Choi; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Successful treatment of disseminated Mycobacterium chelonae infection with linezolid.

Authors:  B A Brown-Elliott; R J Wallace; R Blinkhorn; C J Crist; L B Mann
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

3.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

Authors:  Marina Protopopova; Colleen Hanrahan; Boris Nikonenko; Rowena Samala; Ping Chen; Jackie Gearhart; Leo Einck; Carol A Nacy
Journal:  J Antimicrob Chemother       Date:  2005-09-19       Impact factor: 5.790

4.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Linezolid for the treatment of multidrug-resistant tuberculosis.

Authors:  Jesús Fortún; Pilar Martín-Dávila; Enrique Navas; Ma Jesús Pérez-Elías; Javier Cobo; Marta Tato; Elia Gómez-G De la Pedrosa; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  J Antimicrob Chemother       Date:  2005-05-23       Impact factor: 5.790

7.  Clinical experience with linezolid for the treatment of nocardia infection.

Authors:  Edina H Moylett; Susan E Pacheco; Barbara A Brown-Elliott; Tracy R Perry; E Stephen Buescher; Mary C Birmingham; Jerome J Schentag; Joseph F Gimbel; Aaron Apodaca; Margot A Schwartz; Robert M Rakita; Richard J Wallace
Journal:  Clin Infect Dis       Date:  2003-01-13       Impact factor: 9.079

8.  Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

Authors:  Esteban C Nannini; Michael Keating; Peter Binstock; George Samonis; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072

9.  In vitro activities of new antimicrobials against Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.

Authors:  Lucio Vera-Cabrera; Elsa Y Ochoa-Felix; Gloria Gonzalez; Rolando Tijerina; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  8 in total

1.  In Vitro Activity of Tedizolid against Mycobacterium tuberculosis.

Authors:  Pilar Ruiz; Manuel Causse; Manuel Vaquero; Manuel Casal
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

3.  In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.

Authors:  Huiyun Zhang; Wenya Hua; Siran Lin; Yu Zhang; Xinchang Chen; Shiyong Wang; Jiazhen Chen; Wenhong Zhang
Journal:  Infect Drug Resist       Date:  2022-08-25       Impact factor: 4.177

4.  Antibiotic Susceptibility of Mycobacteria Isolated from Ornamental Fish.

Authors:  Leszek Guz; Krzysztof Puk
Journal:  J Vet Res       Date:  2022-03-25       Impact factor: 2.058

Review 5.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

Review 6.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

7.  Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease.

Authors:  Ravikiran M Raju; Sagar M Raju; Yanlin Zhao; Eric J Rubin
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

Review 8.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.